mirror of
https://github.com/msberends/AMR.git
synced 2026-11-16 06:30:48 +01:00
(v3.1.0.9010) Fix the systematic underestimation of WISCA coverage by only including pathogens that occur in a group and were tested for the regimen, and warn when the prior weight of rare pathogens is large (fixes #337)
This commit is contained in:
1 parent
92bb8931c5
commit
fdfdadae14
6 files changed
+93
-13
No files matched your search
@@ -59,8 +59,8 @@ times](https://scholar.google.com/citations?view_op=view_citation&hl=en&citation
|
||||
in scientific research.
|
||||
|
||||
After installing this package, R knows [**~103 000 distinct microbial
|
||||
species**](./reference/microorganisms.html) (updated April 2026) and all
|
||||
[**~630 antimicrobial and antiviral
|
||||
species**](./reference/microorganisms.html) (updated October 2026) and
|
||||
all [**~630 antimicrobial and antiviral
|
||||
drugs**](./reference/antimicrobials.html) by name and code (including
|
||||
ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all
|
||||
about valid SIR and MIC values. The integral clinical breakpoint
|
||||
@@ -224,7 +224,7 @@ wisca(example_isolates,
|
||||
|
||||
| Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|
||||
|:------------------------|:-------------------------------------|:-------------------------------------|
|
||||
| 70.2% (65-75.4%) | 93.6% (92-95.1%) | 89.9% (87-92.5%) |
|
||||
| 72.5% (67.7-77.1%) | 96% (95.1-96.9%) | 92.1% (89.3-94.4%) |
|
||||
|
||||
WISCA supports stratification by any clinical variable, so you can
|
||||
generate syndrome-specific or ward-specific coverage estimates:
|
||||
@@ -234,13 +234,19 @@ wisca(example_isolates,
|
||||
antimicrobials = c("TZP", "TZP+TOB", "TZP+GEN"),
|
||||
syndromic_group = "ward",
|
||||
minimum = 10) # Recommended threshold: >=30
|
||||
#> Warning: In 6 of 9 WISCA regimen(s) or group(s), the prior weight of 1 per pathogen accounts for more than
|
||||
#> 5% of the pathogen incidence (up to 13.3%), since many pathogens occur only rarely. Because WISCA
|
||||
#> gives every pathogen a prior weight of 1 (Bielicki et al., 2016), such rare pathogens can strongly
|
||||
#> lower the estimated coverage without reflecting the clinical expectation. Consider limiting the
|
||||
#> analysis to the most common pathogens with `top_n_microorganisms()`, or grouping rare pathogens
|
||||
#> before running WISCA.
|
||||
```
|
||||
|
||||
| Syndromic Group | Piperacillin/tazobactam | Piperacillin/tazobactam + Gentamicin | Piperacillin/tazobactam + Tobramycin |
|
||||
|:----------------|:------------------------|:-------------------------------------|:-------------------------------------|
|
||||
| Clinical | 74.8% (69-80.3%) | 93.7% (92.1-95.1%) | 90.4% (86.8-93.3%) |
|
||||
| ICU | 56.7% (48.2-65.4%) | 86.6% (83.3-89.6%) | 83.1% (78.2-87.5%) |
|
||||
| Outpatient | 57.6% (46-69%) | 76.4% (69.8-81.7%) | 68% (57.7-77.5%) |
|
||||
| Clinical | 78% (72.7-83.4%) | 96.3% (95.1-97.3%) | 93% (89.4-95.7%) |
|
||||
| ICU | 59.7% (53.5-67.9%) | 92.2% (90-94.3%) | 88.2% (83.4-92.2%) |
|
||||
| Outpatient | 67.9% (51.9-84.7%) | 92.8% (88.2-96.6%) | 79.8% (64.9-92.9%) |
|
||||
|
||||
**For AMR surveillance**, traditional antibiograms remain the right tool
|
||||
for tracking resistance per species over time:
|
||||
@@ -427,7 +433,7 @@ data analysis. This package can be used for:
|
||||
organisms (MDRO) ([tutorial](./reference/mdro.html))
|
||||
- Calculating (empirical) susceptibility of both mono therapy and
|
||||
combination therapies ([tutorial](./articles/AMR.html))
|
||||
- Apply AMR functions in predictive modelling
|
||||
- Applying AMR functions in predictive modelling
|
||||
([tutorial](./articles/AMR_with_tidymodels.html))
|
||||
- Getting properties for any microorganism (like Gram stain, species,
|
||||
genus or family) ([manual](./reference/mo_property.html))
|
||||
@@ -435,7 +441,8 @@ data analysis. This package can be used for:
|
||||
EARS-Net/ATC/LOINC/PubChem, defined daily dose or trade name)
|
||||
([manual](./reference/ab_property.html))
|
||||
- Plotting antimicrobial resistance ([tutorial](./articles/AMR.html))
|
||||
- Applying EUCAST expert rules ([manual](./reference/eucast_rules.html))
|
||||
- Applying EUCAST and CLSI interpretive rules
|
||||
([manual](./reference/interpretive_rules.html))
|
||||
- Getting SNOMED codes of a microorganism, or getting properties of a
|
||||
microorganism based on a SNOMED code
|
||||
([manual](./reference/mo_property.html))
|
||||
|
||||
Reference in new issue
Block a user